Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FCA Liability After Escobar: Challenges And Opportunities For Device Companies

Executive Summary

A recent Supreme Court decision addressing the False Claims Act holds important implications for medical device companies, according to Gibson Dunn attorneys John D. W. Partridge, Jonathan M. Phillips and Reid F. Rector in this guest column.


Related Content

What Did The Government Know, And When Did Know It? US Supreme Court Seeks Views On False-Claims Case
'Escobar' Conundrum: 2017's Biggest Story In Medtech False-Claims Enforcement
Unlocking Legalities: False-Claim Standards Continue To Evolve
Unlocking Legalities: Ninth Circuit Allows Wider Range Of False Claim Suits
Unusual False-Claims Settlement Cites GMP Issues





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts